electroCore (NASDAQ:ECOR) Stock Struggling Near $1: What’s The Buzz?

Commercial-stage bioelectronics medicine company, electroCore (NASDAQ:ECOR) on July 27, 2021 announced that the United States Patent and Trademark Office had given a Patent No. 11,065,444 for use of a mobile phone to stimulate the trigeminal nerve treating disorders.

This patent has descriptions of devices as well as methods allowing patients to self-treat medical conditions, like migraine, through non-invasive electrical stimulation of nerves, especially supratrochlear, supraorbital,infraorbital, and mental nerves.

Comprising of a handheld mobile device, like a smartphone, applied to patient’s head, it has an electrode sending electrical impulses through skin modulating targeted nerve for treating medical conditions. Designed for addressing problems arising from self-treatment in absence of a medical professional.

JP Errico, a founder, board member and investor of electroCore, said that the company is continuing advancement of non-invasive approaches to treat patients. The inventor of the patent also said that the new development enlarge the scope as well as ease therapy, enabling more number of patients globally to receive such relief at home itself.

The patent is owned by electroCore and is the most latest in non-invasive development program for pain. electroCore is dedicated to improving patient outcomes through its non-invasive nerve stimulation therapy platform.

First non-invasive, hand-held medical therapy, gammaCore is applied at neck for treating migraine as well as cluster headaches. Cleared in the US by the FDA, the acute treatment of pain is CE-marked in the European Union.

Market Reaction:

On Tuesday, ECOR stock jumped 4% at $0.9665 with more than 3.43 million shares, compared to its average volume of 1.94 million shares. The stock has moved within a range of $0.9404 – 1.0200 after opening the trade at $0.99. Over the past 52-week, the stock has been trading within a range of $0.9200 – 3.6300.